Dr. David Mullins - Qu Biologics
Dr. David Mullins has been appointed Chief Scientific Officer at Qu Biologics, responsible for leading the development of the company's Site Specific Immunomodulators and integrating the company's scientific program with its clinical and business development activities.
“Dr. David Mullins is a recognized leader in cancer immunology and his expertise will be instrumental in the development of our SSI platform and the application of our SSIs in the treatment of various cancers and autoimmune diseases,” said CEO Dr. Hal Gunn.
